Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody

BACKGROUND: This study evaluated the efficacy and safety of retreatment with anti‐programmed death 1 (anti‐PD‐1) antibodies in patients with advanced non‐small cell lung cancer (NSCLC) after prior treatment with anti‐programmed death‐ligand 1 (anti‐PD‐L1) antibodies. METHODS: Data (N = 15) on patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Kohei, Yamamoto, Yuki, Kanai, Osamu, Okamura, Misato, Hashimoto, Masayuki, Nakatani, Koichi, Sawai, Satoru, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938769/
https://www.ncbi.nlm.nih.gov/pubmed/31701630
http://dx.doi.org/10.1111/1759-7714.13241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938769/
https://www.ncbi.nlm.nih.gov/pubmed/31701630
http://dx.doi.org/10.1111/1759-7714.13241

Ejemplares similares